Amarin Corporation(US:AMRN)2025-10-29 11:05Financial Performance - Total net revenue for Q3 2025 was $49.7 million, an increase of 17% compared to $42.3 million in Q3 2024[4] - U.S. product revenue increased by 34% to $40.9 million in Q3 2025, up from $30.6 million in Q3 2024[7] - Total revenue for Q3 2025 was $49.67 million, a 17.5% increase from $42.30 million in Q3 2024[36] - Product revenue for Q3 2025 reached $48.56 million, up from $41.85 million in Q3 2024, representing a 15.5% increase[36] - Net loss for Q3 2025 was $7.74 million, compared to a net loss of $25.13 million in Q3 2024, indicating a significant improvement[36] - The company reported a non-GAAP net income of $4.02 million for Q3 2025, compared to a non-GAAP net loss of $20.44 million in Q3 2024[38] Operating Expenses - Operating expenses decreased by 20% to $33.3 million in Q3 2025, down from $41.4 million in Q3 2024[11] - Operating expenses decreased to $33.31 million in Q3 2025 from $41.44 million in Q3 2024, a reduction of 19.6%[36] - The restructuring plan recognized $9.4 million in charges during Q3 2025, impacting overall operating expenses[13] Cash and Investments - Cash and investments at the end of Q3 2025 totaled $286.6 million, down from $298.7 million at the end of Q2 2025[17] - Cash and cash equivalents as of September 30, 2025, were $122.80 million, slightly up from $121.04 million at the end of 2024[34] - Total current assets increased to $628.33 million as of September 30, 2025, compared to $595.40 million at the end of 2024, a growth of 5.5%[34] Loss Improvement - The operating loss improved by 56% to $11.1 million in Q3 2025, compared to a loss of $25.2 million in Q3 2024[16] - Net loss for Q3 2025 was $7.7 million, significantly reduced from $25.1 million in Q3 2024[17] Revenue Sources - Licensing and royalties increased by 149% to $1.1 million in Q3 2025, compared to $0.4 million in Q3 2024[10] Future Outlook - The company is targeting sustainable positive free cash flow in 2026[2] - The transition to a fully partnered commercialization model is expected to enhance market presence across nearly 100 countries[4] - The company anticipates expanding access and reimbursement for VAZKEPA across global markets, with potential strategic collaborations in the pipeline[30] Research and Development - Research and development expenses for Q3 2025 were $4.21 million, consistent with $4.54 million in Q3 2024[36] Gross Margin - Gross margin for Q3 2025 was $22.21 million, compared to $16.28 million in Q3 2024, reflecting a 36.4% increase[36]